Promising Trial

PARP inhibitors finally have some proof, writes Derek Lowe at In the Pipeline. He notes that the drug class has had its ups and downs, as PARP inhibitors developed by various companies haven't always done well in trials — or even always been PARP inhibitors.

But Lowe reports that Tesaro announced yesterday that neraparib, which it licensed from Merck, has shown promising results in ovarian cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.